DOCSLIB.ORG

Monoclonal Antibody Playbook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monoclonal Antibody Playbook Federal Response to COVID-19: Monoclonal Antibody Clinical Implementation Guide Outpatient administration guide for healthcare providers 2 SEPTEMBER 2021 1 Introduction to COVID-19 Monoclonal Antibody Therapy 2 Overview of Emergency Use Authorizations 3 Site and Patient Logistics Site preparation Patient pathways to monoclonal administration 4 Team Roles and Responsibilities Leadership Administrative Clinical Table of 5 Monoclonal Antibody Indications and Administration Indications Contents Preparation Administration Response to adverse events 6 Supplies and Resources Infrastructure Administrative Patient Intake Administration 7 Examples: Sites of Administration and Staffing Patterns 8 Additional Resources 1 1. Introduction to Monoclonal Therapy 2 As of 08/13/21 Summary of COVID-19 Therapeutics 1 • No Illness . Health, no infections • Exposed Asymptomatic Infected . Scope of this Implementation Guide . Not hospitalized, no limitations . Monoclonal Antibodies for post-exposure prophylaxis (Casirivimab + Imdevimab (RGN)) – EUA Issued. • Early Symptomatic . Scope of this Implementation Guide . Not hospitalized, with limitations . Monoclonal Antibodies for treatment (EUA issued): Bamlanivimab + Etesevimab1 (Lilly) Casirivimab + Imdevimab (RGN) Sotrovimab (GSK/Vir) • Hospital Adminission. Treated with Remdesivir (FDA Approved) or Tocilizumab (EUA Issued) . Hospitalized, no acute medical problems . Hospitalized, not on oxygen . Hospitlaized, on oxygen • ICU Admission . Hospitalized, high flow oxygen, non-invasive ventilation . Hospitalized, mechanical ventilation/ECMO 1. Not authorized for use in states, territories, and US jurisdictions in which the combined frequency of variants resistant to bamlanivimab and etesevimab exceeds 5%. A list of states, territories, and US jurisdictions in which bamlanivimab and etesevimab are and are not currently authorized is available on the following FDA website: https://www.fda.gov/media/151719/download 3 1 Potential Mechanisms for the Clinical Effects of Monoclonal Antibodies Mechanism 1: neutralizing antibodies could block viral infection by binding to the viral spike protein and preventing it from interacting with the cellular receptor angiotensin-converting enzyme 2 (ACE2). Mechanism 2: neutralizing antibodies could bind to the viral spike protein and block the conformational changes that the spike protein must undergo to facilitate fusion of the viral and host cell membranes. b | Antibodies could enhance viral entry into immune cells by binding to the viral spike protein with their Fab portion and to Fc receptors (FcRs) with their Fc domain. Source: Nature • Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent progression of disease • mAbs are most effective when given early in infection 4 Monoclonal Antibodies and Variants of Concern 1 • Estimated biweekly proportions of the most common SARS-CoV-2 lineages circulating in the U.S available from the CDC variant proportions data tracker1. (See sample below). Providers should assess variant prevalence in their geographic area when choosing mAb • Information on variants of concern updated in Section 15 of FDA fact sheets2,3 1. CDC Variant tracker 5 2. FDA factsheets: REGEN-COVTM (www.fda.gov/media/145611/download); bamlanivimab and etesevimab (https://www.fda.gov/media/145802/download) 3. WHO Tracking SARS-CoV-2 Variants (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ ) As of 08/13/21 1 Review of Clinical Data (I/II) Date Source Trial design / Reported outcomes Notes patients Jan 2021 JAMA RCT, n = 577 • 70% reduction in hospitalization for high-risk patients Lillly trial (Ph 2) • 50% decrease in hospitalizations, 40% decrease in emergency Feb 2021 Website Observational St. Luke's department visits Mar 2021 Lily RCT, n = 769 • 87% relative reduction vs. placebo in hospitalizations / death Lilly trial (Ph 3) Regenero Mar 2021 RCT, n = 4,567 • 70% relative reduction vs. placebo in hospitalizations / death Regen. trial (Ph 3) n • 4.2% hospitalization rate for those treated with mAbs vs. 9-14.6% Observational, Mar 2021 NEJM reported for untreated high-risk Houston Methodist n not listed • Only 13% felt symptoms progressed after therapy • Patients receiving mAb had 69% lower odds of hospitalization or Observational, mortality, and 50% lower odds of hospitalization or ED visit without Mar 2021 Medrxiv n = 234 UPMC hospitalization matched, • 6% hospitalization in treated vs. 16.2% untreated, Observational, • 1.9% of treated patients presented to E.D. / required hospitalization Apr 2021 Medrxiv n = 270 treated, ASPR vs. 12% of untreated 328 untreated 6 As of 08/13/21 1 Review of Clinical Data (II/II) Date Source Trial design / Reported outcomes Notes patients • Hospitalization rate was 4.4% for patients who received MAB therapy Observational, n Apr 2021 Medrxiv w/in 0-4 days, 5% w/in 5-7 days, and 6.1% w/in ≥8 days of symptom Northwell Health = 2,818 onset (p = 0.15) • 2400mg & 1200mg drugs sig. reduced hospitalization or all-cause death Medrxiv May 2021 RCT, n = 4,057 compared to placebo (71.3% reduction [1.3% vs 4.6%; p<0.0001] and Regen. trial (preprint) 70.4% reduction [1.0% vs 3.2%; p=0.0024], respectively • Bam significantly reduced the incidence of COVID-19 in the prevention Jun 2021 JAMA RCT, n = 1175 population compared with placebo (p<.001) at skilled nursing/assisted Lilly trial (Ph 3) living facilities • Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household Aug 2021 NEJM RCT, n = 2475 contacts of infected persons (p<0.001) Regen. trial • Among participants who became infected, REGEN-COV reduced duration of symptomatic disease and high viral load (p<0.001) 7 1 Monoclonal Antibody Safety Data Monoclonal Reported Safety Data Antibody • Blaze 1 Trial Phase 3 Data (bamlanivimab 700mg and etesevimab 1400mg): Treatment n=511, Placebo n=258 . bamlanivimab and etesevimab Deaths: 0 in treatment group, 4 in placebo group . Adverse reactions observed in those who received bamlanivimab and etesevimab were anaphylaxis (n=1, 0.7%) https://www.covid19.lilly.com/bam- and infusion-related reactions (n=16, 1.1%. The most common treatment-emergent adverse events included ete/hcp/clinical-data nausea, dizziness, and pruritis. No treatment-emergent events occurred in more than 1% of participants and were comparable with placebo • ~16,000 subjects studies in clinical trials (~13,500 received intravenous infusion and 2,500 subcutaneous injection) REGEN-COV • COV-2067 (Phase 3 trial of non-hospitalized subjects receiving intravenous administration): 0/827 patients in the casirivimab and imdevimab treatment arm had a reaction requiring termination of the infusion (urticaria, pruritis, flushing, pyrexia, shortness of breath, chest tightness, nausea, vomiting, rash) https://www.regencov.com/hcp/clinical- information/safety • COV-2069 (PEP in COVID-19 negative individuals exposed to a household member; n= 1311): Injection site reactions (erythema, pruritis) 4% in treatment group/ 2% in placebo group. No cases of anaphylaxis sotrovimab • COMET-ICE: ongoing clinical trial in non-hospitalized patients . Infusion related reactions, including immediate hypersensitivity, observed in 1% of treatment group and 1% of https://www.sotrovimab.com/hcp/clinical- placebo group safety-variant-info/ . Most common treatment-emergent adverse events (all were grade 1- mild, or grade 2-moderate): rash (2%) diarrhea (1%), no other events were reported at a higher rate with treatment compared to placebo For non-severe infusion-related reactions, consider slowing or stopping the infusion and administer appropriate medications 8 2. Overview of Emergency Use Authorization 9 2 The Role of Emergency Use Authorization (EUA) in COVID-19 Therapeutics Q: What is an emergency use authorization and how is it being used to respond to COVID-19 A: In certain types of emergencies, the FDA can issue an emergency use authorization, or EUA, to provide more timely access to critical medical products (including medicines and tests) that may help during the emergency when there are no adequate, approved, and available alternative options. The EUA process is different than FDA approval, clearance, or licensing because the EUA standard may permit authorization based on significantly less data than would be required for approval, clearance, or licensing by the FDA. This enables the FDA to authorize the emergency use of medical products that meet the criterial within weeks rather than months to years. EUAs are in effect until the emergency declaration ends but can be revised or revoked as we evaluate the needs during the emergency and new data on the product’s safety and effectiveness, or as products meet the criteria to become approved, cleared, or licensed by the FDA. About Emergency Use Autorizations (EUAs) https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#abouteuas 10 Indications for Outpatient COVID-19 mAbs Monoclonal Antibody Indications and Routes of Administration TREATMENT of Mild to Moderate COVID-19 Infection POST-EXPOSURE PROPHYLAXIS for individuals Monoclonal Antibody within 10 days of symptom onset in patient with high risk of who are not fully vaccinated or immunocompromised, progression to severe disease with high risk of progression to severe disease bamlanivimab and Dose: 700 mg bamlanivimab and 1400 mg etesevimab*** etesevimab1 Route: Intravenous administration N/A (Eli
Load more

Recommended publications
  • Lactoferrin and Its Detection Methods: a Review
    nutrients Review Lactoferrin and Its Detection Methods: A Review Yingqi Zhang, Chao Lu and Jin Zhang * Department of Chemical and Biochemical Engineering, University of Western Ontario, London, ON N6A 5B9, Canada; [email protected] (Y.Z.); [email protected] (C.L.) * Correspondence: [email protected] Abstract: Lactoferrin (LF) is one of the major functional proteins in maintaining human health due to its antioxidant, antibacterial, antiviral, and anti-inflammatory activities. Abnormal levels of LF in the human body are related to some serious diseases, such as inflammatory bowel disease, Alzheimer’s disease and dry eye disease. Recent studies indicate that LF can be used as a biomarker for diagnosis of these diseases. Many methods have been developed to detect the level of LF. In this review, the biofunctions of LF and its potential to work as a biomarker are introduced. In addition, the current methods of detecting lactoferrin have been presented and discussed. We hope that this review will inspire efforts in the development of new sensing systems for LF detection. Keywords: lactoferrin; biomarkers; immunoassay; instrumental analysis; sensor 1. Introduction Lactoferrin (known as lactotransferrin, LF), with a molecular weight of about 80 kDa, is a functional glycoprotein, which contains about 690 amino acid residues. It was first isolated from bovine milk by Sorensen in 1939 and was first isolated from human milk by Citation: Zhang, Y.; Lu, C.; Zhang, J. Johanson in 1960 [1,2]. The three-dimensional structure of LF has been unveiled by high Lactoferrin and Its Detection resolution X-ray crystallographic analysis, and it consists of two homologous globular lobes Methods: A Review.
    [Show full text]
  • Emergency Use Authorization (EUA) for Sotrovimab 500 Mg Center for Drug Evaluation and Research (CDER) Review
    Emergency Use Authorization (EUA) for Sotrovimab 500 mg Center for Drug Evaluation and Research (CDER) Review Identifying Information Application Type EUA (EUA or Pre-EUA) If EUA, designate whether pre-event or intra-event EUA request. EUA Application EUA 000100 Number(s) Sponsor (entity EUA Sponsor requesting EUA or GlaxoSmithKline Research & Development Limited pre-EUA 980 Great West Road consideration), point Brentford Middlesex, TW8 9GS of contact, address, UK phone number, fax number, email GSK US Point of Contact address Debra H. Lake, M.S. Sr. Director Global Regulatory Affairs GlaxoSmithKline 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709-3398 (b) (6) Email: Phone Manufacturer, if GlaxoSmithKline, Parma. different from Sponsor Submission Date(s) Part 1: March 24, 2021 Part 2: March 29, 2021 Receipt Date(s) Part 1: March 24, 2021 Part 2: March 29, 2021 OND Division / Office Division of Antivirals /Office of Infectious Disease 1 Reference ID: 4802027 Product in the No Strategic National Stockpile (SNS) Distributor, if other (b) (4) than Sponsor I. EUA Determination/Declaration On February 4, 2020, the Secretary of Health and Human Services determined pursuant to section 564 of the Federal Food, Drug and Cosmetic (FD&C) Act that there is a public health emergency that has a significant potential to affect national security or the health and security of United States (US) citizens living abroad and that involves a novel (new) coronavirus (nCoV) first detected in Wuhan City, Hubei Province, China in 2019 (2019-nCoV). The virus is now named SARS-CoV-2, which causes the illness COVID-19.
    [Show full text]
  • Mark Taylor; [email protected]; (317) 276-5795 (Media) Kevin Hern; Hern Kevin [email protected]; (317) 277-1838 (Investors)
    January 29, 2021 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Media) Kevin Hern; [email protected]; (317) 277-1838 (Investors) Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results • Revenue in the fourth quarter of 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent. • Full-year 2020 revenue increased 10 percent, driven by volume growth of 15 percent. Excluding bamlanivimab, full-year 2020 revenue grew 6 percent, driven by volume growth of 11 percent. • Key growth products launched since 2014, consisting of Trulicity, Verzenio, Taltz, Tyvyt, Olumiant, Jardiance, Emgality, Cyramza, Retevmo, Baqsimi and Basaglar contributed nearly 12 percentage points of revenue growth and represented approximately 48 percent of total revenue in the fourth quarter of 2020, or 55 percent of total revenue excluding bamlanivimab. • Fourth-quarter 2020 operating expenses increased 3 percent, driven by higher research and development investments, including expenses of $265 million to develop COVID-19 therapies. • Notable pipeline events included Emergency Use Authorizations from the FDA for both bamlanivimab and baricitinib for the treatment of COVID-19, as well as positive data readouts for donanemab for Alzheimer's disease, tirzepatide for type 2 diabetes and LOXO-305 for cancer. • Fourth-quarter 2020 earnings per share (EPS) increased to $2.32 on a reported basis and $2.75 on a non- GAAP basis. Full year 2020 EPS decreased to $6.79 on a reported basis and increased to $7.93 on a non- GAAP basis.
    [Show full text]
  • Drug Information Center Highlights of FDA Activities
    Drug Information Center Highlights of FDA Activities – 3/1/21 – 3/31/21 FDA Drug Safety Communications & Drug Information Updates: Ivermectin Should Not Be Used to Treat or Prevent COVID‐19: MedWatch Update 3/5/21 The FDA advised consumers against the use of ivermectin for the treatment or prevention of COVID‐19 following reports of patients requiring medical support and hospitalization after self‐medicating. Ivermectin has not been approved for this use and is not an anti‐viral drug. Health professionals are encouraged to report adverse events associated with ivermectin to MedWatch. COVID‐19 EUA FAERS Public Dashboard 3/15/21 The FDA launched an update to the FDA Adverse Event Reporting System (FAERS) Public Dashboard that provides weekly updates of adverse event reports submitted to FAERS for drugs and therapeutic biologics used under an Emergency Use Authorization (EUA) during the COVID‐19 public health emergency. Monoclonal Antibody Products for COVID‐19 – Fact Sheets Updated to Address Variants 3/18/21 The FDA authorized revised fact sheets for health care providers to include susceptibility of SARS‐CoV‐2 variants to each of the monoclonal antibody products available through EUA for the treatment of COVID‐19 (bamlanivimab, bamlanivimab and etesevimab, and casirivimab and imdevimab). Abuse and Misuse of the Nasal Decongestant Propylhexedrine Causes Serious Harm 3/25/21 The FDA warned that abuse and misuse of the nasal decongestant propylhexedrine, sold OTC in nasal decongestant inhalers, has been increasingly associated with cardiovascular and mental health problems. The FDA has recommended product design changes to support safe use, such as modifications to preclude tampering and limits on the content within the device.
    [Show full text]
  • USAN Naming Guidelines for Monoclonal Antibodies |
    Monoclonal Antibodies In October 2008, the International Nonproprietary Name (INN) Working Group Meeting on Nomenclature for Monoclonal Antibodies (mAb) met to review and streamline the monoclonal antibody nomenclature scheme. Based on the group's recommendations and further discussions, the INN Experts published changes to the monoclonal antibody nomenclature scheme. In 2011, the INN Experts published an updated "International Nonproprietary Names (INN) for Biological and Biotechnological Substances—A Review" (PDF) with revisions to the monoclonal antibody nomenclature scheme language. The USAN Council has modified its own scheme to facilitate international harmonization. This page outlines the updated scheme and supersedes previous schemes. It also explains policies regarding post-translational modifications and the use of 2-word names. The council has no plans to retroactively change names already coined. They believe that changing names of monoclonal antibodies would confuse physicians, other health care professionals and patients. Manufacturers should be aware that nomenclature practices are continually evolving. Consequently, further updates may occur any time the council believes changes are necessary. Changes to the monoclonal antibody nomenclature scheme, however, should be carefully considered and implemented only when necessary. Elements of a Name The suffix "-mab" is used for monoclonal antibodies, antibody fragments and radiolabeled antibodies. For polyclonal mixtures of antibodies, "-pab" is used. The -pab suffix applies to polyclonal pools of recombinant monoclonal antibodies, as opposed to polyclonal antibody preparations isolated from blood. It differentiates polyclonal antibodies from individual monoclonal antibodies named with -mab. Sequence of Stems and Infixes The order for combining the key elements of a monoclonal antibody name is as follows: 1.
    [Show full text]
  • REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2017 (February 9, 2017) REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) New York 000-19034 13-3444607 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File No.) Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices, including zip code) (914) 847-7000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 2.02 Results of Operations and Financial Condition. On February 9, 2017, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2016. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
    [Show full text]
  • Pharmacy Market Outlook Highlights Keeping You at the Forefront of Drug Price Projections and Market Developments
    SUMMER 2021 Pharmacy Market Outlook Highlights Keeping you at the forefront of drug price projections and market developments VIZIENT CENTER FOR PHARMACY PRACTICE EXCELLENCE 1 Pharmacy Market Outlook Summer 2021 Highlights © 2021 Vizient, Inc. All rights reserved. Table of contents Overview Executive summary ......................................................................................................3 Key findings by segment Acute care ......................................................................................................................6 Projections by therapeutic class Specialty pharmaceuticals ..........................................................................................7 Pediatrics .......................................................................................................................8 Oncology ........................................................................................................................9 Infectious disease .......................................................................................................10 Immunomodulators and disease-modifying therapies ........................................11 Plasma products: Intravenous immune globin and albumin ................................12 New: diabetes-related medications .........................................................................13 Management of high-cost therapies Biologics and biosimilars ...........................................................................................14 The evolution
    [Show full text]
  • The Future of Antibodies As Cancer Drugs
    REVIEWS Drug Discovery Today Volume 17, Numbers 17/18 September 2012 The biopharmaceutical industry’s pipeline of anticancer antibodies includes 165 candidates with substantial diversity in composition, targets and mechanisms of action that hold promise to be the cancer drugs of the future. Reviews FOUNDATION REVIEW Foundation review: The future of antibodies as cancer drugs 1 2 Dr Janice Reichert Janice M. Reichert and Eugen Dhimolea is Research Assistant Professor at Tufts 1 Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, University’s Center for the Study of Drug Development Suite 1100, Boston, MA 02111, USA 2 (CSDD). She is also Founder Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, 77 Louis Pasteur Ave., and Editor-in-Chief of mAbs, Harvard Institutes of Medicine, Room 309, Boston, MA 02215, USA a peer-reviewed, PubMed- indexed biomedical journal that focuses on topics relevant to antibody research Targeted therapeutics such as monoclonal antibodies (mAbs) have proven and development; President of the board of directors of The Antibody Society; and a member of the board successful as cancer drugs. To profile products that could be marketed in of the Peptide Therapeutics Foundation. At CSDD, the future, we examined the current commercial clinical pipeline of mAb Dr Reichert studies innovation in the pharmaceutical and biotechnology industries. Her work focuses on candidates for cancer. Our analysis revealed trends toward development of strategic analyses of investigational candidates and marketed products, with an emphasis on the clinical a variety of noncanonical mAbs, including antibody–drug conjugates development and approval of new therapeutics and (ADCs), bispecific antibodies, engineered antibodies and antibody vaccines.
    [Show full text]
  • CYRAMZA (Ramucirumab) Injection Label
    1 HIGHLIGHTS OF PRESCRIBING INFORMATION • 500 mg/50 mL (10 mg per mL) solution, single-dose vial (3) These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information ------------------------------- CONTRAINDICATIONS ------------------------------ for CYRAMZA. None CYRAMZA (ramucirumab) injection, for intravenous infusion ------------------------ WARNINGS AND PRECAUTIONS ----------------------- Initial U.S. Approval: 2014 • Arterial Thromboembolic Events (ATEs): Serious, sometimes fatal WARNING: HEMORRHAGE ATEs have been reported in clinical trials. Discontinue CYRAMZA for severe ATEs. (5.2) See full prescribing information for complete boxed warning. • Hypertension: Monitor blood pressure and treat hypertension. CYRAMZA increased the risk of hemorrhage, including severe Temporarily suspend CYRAMZA for severe hypertension. and sometimes fatal hemorrhagic events. Permanently Discontinue CYRAMZA for hypertension that cannot be medically discontinue CYRAMZA in patients who experience severe controlled. (5.3) bleeding [see Dosage and Administration (2.3), Warnings and • Infusion-Related Reactions: Monitor for signs and symptoms Precautions (5.1)]. during infusion. (5.4) • Gastrointestinal Perforation: Discontinue CYRAMZA. (5.5) --------------------------- RECENT MAJOR CHANGES -------------------------- • Impaired Wound Healing: Withhold CYRAMZA prior to surgery. Indications and Usage 11/2014 (5.6) • Clinical Deterioration in Patients with Cirrhosis: New onset or Dosage and Administration:
    [Show full text]
  • COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody
    Review Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.29.004828 COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody Basma H Marghani* Department of Physiology, Faculty of Veterinary Medicine, Mansoura University, Egypt *Corresponding author: Basma H Marghani, Department of Physiology, Faculty of Veterinary Medicine, Mansoura University, Egypt ARTICLE INFO ABSTRACT Received: August 10, 2020 Published: August 18, 2020 rapidly to the other countries all over the world, caused a novel Coronavirus-2019 (COV- SARS-CoV-2 was appeared firstly in Wuhan, China in December 2019, then spread- gency. After infection, virus entry the host cell through spike proteins (S)- angiotensin Citation: Basma H Marghani. COVID-19 ID-19). The World Health Organization was branded COVID-19 as a global health emer Immunotherapy: Novel Humanized 47D11 converting enzyme 2 (ACE2) cell membrane receptor via their S-Binding domain, then Monoclonal Antibody. Biomed J Sci & Tech virus replication caused acute respiratory disease syndrome (ARDS). Till now there was Res 29(4)-2020. BJSTR. MS.ID.004828. no vaccines or anti-viral drugs for coronavirus infection. One effective treatment is the use of human monoclonal antibodies (mAbs) which are engineered to target and block Keywords: COVID-19; Immunotherapy; cell surface receptor. mAbs could be given to people in the early stages of COVID-19 as a Full-Length Humanized Monoclonal Anti- therapeutic, or used prophylactically to give immediate, long-term immunity to vulnera- bodies; ACE Inhibitor ble people such as healthcare workers. The neutralizing humanized 47D11 monoclonal antibody targets a common epitope on SARS-CoV2 virus and may offer potential for pre- Abbreviations: ACE2: Angiotensin-Con- vention and treatment of COVID-19.89U (Graphical Abstract 1).
    [Show full text]
  • Frequently Asked Questions on the Emergency Use Authorization for Bamlanivimab and Etesevimab
    Frequently Asked Questions on the Emergency Use Authorization for Bamlanivimab and Etesevimab Q. What is an Emergency Use Authorization (EUA)? A: Under section 564 of the Federal Food, Drug & Cosmetic Act, after a declaration by the HHS Secretary based on one of four types of determinations, FDA may authorize an unapproved product or unapproved uses of an approved product for emergency use. In issuing an EUA, FDA must determine, among other things, that based on the totality of scientific evidence available, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing a serious or life-threatening disease or condition caused by a chemical, biological, radiological, or nuclear agent; that the known and potential benefits, when used to treat, diagnose or prevent such disease or condition, outweigh the known and potential risks for the product; and that there are no adequate, approved, and available alternatives. Emergency use authorization is NOT the same as FDA approval or licensure. Q. What does this EUA authorize? A. The EUA authorizes Eli Lilly and Company’s (Lilly’s) bamlanivimab and etesevimab, administered together, for emergency use for both treatment and as post-exposure prophylaxis (prevention) of COVID-19. Treatment: Treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
    [Show full text]
  • Ab200015 Human Lactoferrin Simplestep ELISA® Kit
    Version 1 Last updated 28 August 2019 ab200015 Human Lactoferrin SimpleStep ELISA® Kit For the quantitative measurement of Lactoferrin in human serum, plasma, milk, urine, saliva, and cell culture supernatants. This product is for research use only and is not intended for diagnostic use. Copyright © 2018 Abcam. All rights reserved Table of Contents 1. Overview 1 2. Protocol Summary 2 3. Precautions 3 4. Storage and Stability 3 5. Limitations 4 6. Materials Supplied 4 7. Materials Required, Not Supplied 5 8. Technical Hints 5 9. Reagent Preparation 7 10. Standard Preparation 8 11. Sample Preparation 9 12. Plate Preparation 11 13. Assay Procedure 12 14. Calculations 14 15. Typical Data 15 16. Typical Sample Values 16 17. Assay Specificity 23 18. Species Reactivity 23 19. Troubleshooting 24 20. Notes 25 Technical Support 26 Copyright © 2018 Abcam. All rights reserved 1. Overview Lactoferrin in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Lactoferrin protein in humanserum, plasma, milk, urine, saliva, and cell culture supernatants. The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB Development Solution is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow.
    [Show full text]